Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Management of Crohn's disease Stories

2013-12-16 08:27:16

Oral 5-Aminosalicylates Will Remain the Preferred Treatment Regimen for Early Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through an examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has experienced steady growth among recently treated Crohn's disease (CD)...

2013-08-19 08:28:31

SUSTAIN study to investigate the potential of a chronic SelG1 therapy to reduce or prevent the occurrence of sickle cell-related pain crises OKLAHOMA CITY, Aug. 19, 2013 /PRNewswire/ -- Selexys Pharmaceuticals Corporation, a privately held biopharmaceutical company that is developing therapies to treat inflammatory and thrombotic diseases, today announced that enrollment has been initiated in SUSTAIN, a Phase II, multicenter, randomized, placebo-controlled, double-blind, 12-month...

2013-06-27 08:30:51

Surveyed U.S. Payers Are Particularly Receptive to New Therapies That Offer Improved Effect on Induction and Maintenance of Remission Over Currently Available Agents, According to a New Report from Decision Resources BURLINGTON, Mass., June 27, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that enables a greater percentage of patients to maintain remission is one of the...

2013-06-26 20:40:43

More people are being affected by drug-induced liver injury (DILI) than ever before, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. This type of liver injury results from the use of certain prescription and over-the-counter medications, as well as dietary supplements, and is among the more challenging forms of liver disease due to its difficulty to predict, diagnose and manage. Investigators conducted a population-based...

2013-05-15 08:29:48

PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has...

2013-03-11 13:22:56

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with...

2012-09-06 02:31:26

PRINCETON, N.J., Sept. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of pediatric Crohn's disease. Soligenix has previously received Orphan Drug Designation for oral BDP...